ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
123.906,55
-0,32%
S&P 500
5.460,48
-0,41%
US Dollar vs BRL
5,5936
0,00%
Bitcoin
60.848,29
0,89%
Brent Oil
84,85
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Abeona Therapeutics Inc (ABEO)

  7. Abeona Therapeutics Inc (ABEO) Notícias

ABEO

Abeona Therapeutics (ABEO)

Abeona Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ABEO
DataHoraFonteTítuloCódigoCompanhia
17/06/202418:17Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ABEOAbeona Therapeutics Inc
17/06/202417:47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABEOAbeona Therapeutics Inc
12/06/202408:01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ABEOAbeona Therapeutics Inc
07/06/202417:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABEOAbeona Therapeutics Inc
03/06/202417:30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ABEOAbeona Therapeutics Inc
03/06/202408:30GlobeNewswire Inc.Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ABEOAbeona Therapeutics Inc
28/05/202408:30GlobeNewswire Inc.Abeona Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:ABEOAbeona Therapeutics Inc
15/05/202417:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ABEOAbeona Therapeutics Inc
15/05/202408:35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABEOAbeona Therapeutics Inc
15/05/202408:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABEOAbeona Therapeutics Inc
15/05/202408:30GlobeNewswire Inc.Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate ProgressNASDAQ:ABEOAbeona Therapeutics Inc
13/05/202418:03Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ABEOAbeona Therapeutics Inc
03/05/202408:30GlobeNewswire Inc.Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsNASDAQ:ABEOAbeona Therapeutics Inc
22/04/202417:05GlobeNewswire Inc.Abeona Therapeutics Provides Regulatory Update on Pz-celNASDAQ:ABEOAbeona Therapeutics Inc
18/03/202408:30GlobeNewswire Inc.Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA InspectionsNASDAQ:ABEOAbeona Therapeutics Inc
01/02/202409:30GlobeNewswire Inc.Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)NASDAQ:ABEOAbeona Therapeutics Inc
08/01/202409:30GlobeNewswire Inc.Abeona Therapeutics Announces $50 Million Credit FacilityNASDAQ:ABEOAbeona Therapeutics Inc
27/11/202309:30GlobeNewswire Inc.Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)NASDAQ:ABEOAbeona Therapeutics Inc
13/11/202309:30GlobeNewswire Inc.Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate DevelopmentsNASDAQ:ABEOAbeona Therapeutics Inc
26/09/202308:30GlobeNewswire Inc.Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis BullosaNASDAQ:ABEOAbeona Therapeutics Inc
12/09/202308:30GlobeNewswire Inc.Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial OfficerNASDAQ:ABEOAbeona Therapeutics Inc
07/09/202308:30GlobeNewswire Inc.Abeona Therapeutics Announces Participation in Upcoming Investor ConferencesNASDAQ:ABEOAbeona Therapeutics Inc
30/08/202308:30GlobeNewswire Inc.Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA SubmissionNASDAQ:ABEOAbeona Therapeutics Inc
08/08/202308:30GlobeNewswire Inc.Abeona Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:ABEOAbeona Therapeutics Inc
28/07/202308:30GlobeNewswire Inc.Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023NASDAQ:ABEOAbeona Therapeutics Inc
19/07/202309:30GlobeNewswire Inc.Abeona Therapeutics Joins Rare Disease Company CoalitionNASDAQ:ABEOAbeona Therapeutics Inc
10/07/202311:41Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ABEOAbeona Therapeutics Inc
07/07/202309:30GlobeNewswire Inc.Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:ABEOAbeona Therapeutics Inc
03/07/202309:45GlobeNewswire Inc.Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:ABEOAbeona Therapeutics Inc
03/07/202309:34Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ABEOAbeona Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ABEO

Seu Histórico Recente

EU
FR0128199868
CA Consumer Finance Cacf...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados